3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
6
Wilms Tumor
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Xanthogranuloma, Juvenile
1
Histiocytic Sarcoma
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Biliary Tract Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Cisplatin
5
Gemcitabine
4
Oxaliplatin
2
Irinotecan
2
Fluorouracil
2
Capecitabine
2
Bevacizumab
2
zanidatamab
1
toripalimab
1
pembrolizumab
1
niraparib
1
neratinib
1
ivosidenib
1
futibatinib
1
fludarabine
1
envafolimab
1
encorafenib
1
durvalumab
1
binimetinib
1
Trastuzumab
1
Pemetrexed
1
Nivolumab
1
Folfox protocol
1
Docetaxel
1
Cyclophosphamide
1
Cetuximab
1
Carboplatin
1
Actigraphy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
ivosidenib
×
30 days
×
Clear all
NCT05615818
2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3
Recruiting
800 enrolled